Epidemiology of upper limb skin and soft tissue infections requiring surgical intervention in Saskatoon, Canada: A retrospective chart review

Epidemiology of upper limb skin and soft tissue infections requiring surgical intervention in Saskatoon, Canada: A retrospective chart review | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Epidemiology of upper limb skin and soft tissue infections requiring surgical intervention in Saskatoon, Canada: A retrospective chart review Emma J Yanko, Rachel L Miller, Retaj H Ramadan, Gary Groot, Chris Thomson This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4004749/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background : Skin and soft tissue infections (SSTIs) are a leading cause of hospital admission and engagement with the health care system amongst people who inject drugs (PWID). The current study aims to describe the epidemiology of SSTIs requiring surgical intervention in Saskatoon, Canada. Methods : This retrospective chart review assessed patients with a primary diagnosis of upper limb SSTIs requiring surgical intervention at St. Paul’s Hospital and Royal University Hospital (Saskatoon, Canada) between January 1 and December 31, 2020. Results : 38 eligible patients with a median age of 34 years and M:F of 21:17 were identified. 31 (81.6%) smoked cigarettes and 19 (50.0%) used intravenous drugs. A majority of SSTIs were unilateral infections involving the hand 22 (57.9%) or upper arm 11 (28.9%). Ten (26.3%) patients had a prior SSTI requiring surgical management. Necrotizing fasciitis was diagnosed in 7 (18.4%) patients, two of which, required amputation of the affected hand or arm. The median length of hospital stay was 6 days (IQR: 4 – 14.5). Ten patients left the hospital against medical advice, before completion of treatment; of these patients, 8 (80.0%) were PWID. Conclusion : Harm reduction strategies may help address the rising incidence and recurrence of SSTIs in the injection drug use population. Involvement of addiction services and social work during hospital admission may reduce the rate of patient-directed discharge, facilitating the completion of treatment. Furthermore, increased access to needle exchange programs in the community may reduce the number of SSTIs caused by contaminated injection equipment in the PWID population. Harm Reduction Necrotizing Fasciitis Soft Tissue Infections Substance Abuse Intravenous Figures Figure 1 Figure 2 Figure 3 BACKGROUND Intravenous drug use (IVDU) is associated with significant morbidity and mortality. In 2016, the national population prevalence of people who inject drugs (PWID) in Canada was reported to be 0.70 per 100 persons aged 15 to 64. In Saskatchewan, however, the provincial population prevalence was much greater at 0.97 per 100 persons aged 15 to 64 years. 1 IVDU is the most common risk factor for the acquisition of both hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in Saskatchewan. Consequently, Saskatchewan has a significantly higher incidence of new HCV and HIV diagnoses compared to the national rate. 2 – 4 People who inject drugs are at increased risk for the development of bacterial, fungal, and blood-borne infections; often spread via the use of contaminated injection drug supplies, unsanitary conditions, and low vaccination rates in these populations. 5 , 6 Skin and soft tissue infections (SSTIs) exemplify the infections that contribute to morbidity and mortality in PWID. 7 Studies in both Canada and the United States have found that SSTIs represent a leading cause of hospitalization and engagement with the healthcare system in PWID. 8 , 9 The management of SSTIs often requires long hospital admissions, and surgical interventions, resulting in high healthcare associated costs. In addition, several studies report the average cost of hospitalization in PWID to be greater than in patients who do not use injection drugs. 2 , 10 There is an urgent need to better understand and recognize the characteristics of patients admitted to hospitals with SSTIs in Canada. This study aimed to describe the epidemiology, hospital course, and prevalence of injection drug use in patients with a primary diagnosis of upper limb SSTIs requiring surgical intervention at St. Paul’s Hospital and Royal University Hospital (Saskatoon, Canada) between January 1 and December 31, 2020. Additionally, we sought to describe harm reduction strategies aimed at preventing the development of SSTIs in the PWID population. METHODS Study Design This retrospective chart review involved patients with upper limb skin and soft tissue infection who were admitted to St. Paul’s Hospital or Royal University Hospital (Saskatoon, SK, CA) between January 1, 2020, and December 31, 2020. Patients were excluded if the soft tissue infection did not involve the upper limb (hand to shoulder) or did not require surgical intervention. The University of Saskatchewan Biomedical Research Ethics Board approved the study protocol (Bio 2875). International Classification of Disease codes (ICD) were used to identify eligible patients from the Saskatchewan Health Authority medical records database. Data Collection A pre-determined data abstraction sheet was used for data collection and one researcher (RM) collected the data. Data was organized within 10 predetermined categories: patient demographics (age, gender, smoking, injection drug use, comorbidities), location of infection, prior SSTIs requiring surgical intervention, choice of antibiotic, mode of antibiotic, culture results, time from initial presentation to procedure, length of stay, repeat procedures, and hospital discharge. Statistical Analysis Descriptive statistics were performed to summarize the characteristics of the studied population including demographics, course in hospital, antibiotic treatment, culture results, and infection classification. Categorical data was analyzed as frequency and the corresponding proportion using Microsoft Excel. RESULTS A total of 132 patients were identified. Of these, 94 patients were excluded due to the anatomic location of the SSTI or lack of surgical intervention. Of the 38 patients included in the study, the median patient age was 34 years (IQR: 28 to 49 years) and the male: female ratio was 21:17. Among these, 31 (81.6%) smoked cigarettes and 19 (50.0%) used intravenous drugs. The most common comorbidity reported was type 2 diabetes mellitus in 7 (18.4%) patients. One patient was noted to be taking immunosuppressive medication and one patient had end-stage renal disease. Ten (26.3%) patients had a prior soft tissue infection requiring surgical management. A majority of the skin and soft tissue infections assessed in this study were unilateral infections; either involving the hand 22 (57.9%) or the upper arm 11 (28.9%). Three cases involved the bilateral hands (7.9%) and two cases involved the unilateral wrist (5.3%). There were no bilateral upper arm or bilateral wrist infections diagnosed in the study population (Table 1 ). Necrotizing fasciitis was diagnosed in 7 (18.4%) patients in this sample and was most commonly associated with Streptococcus pyogenes (GAS) (Fig. 1 ). The most common microbe cultured in all assessed SSTIs was GAS 17 (44.7%). Methicillin-resistant Staphylococcus aureus (MRSA) was cultured in 5 (13.2%) patients and Methicillin-susceptible Staphylococcus aureus (MSSA) in 4 (10.5%) cases. Four of the patients (11%) had culture-negative results and 6 (15.7%) grew multiple organisms; of these, four grew both Streptococcus pyogenes and Streptococcus agalactiae (GBS) (Fig. 2 ). All patients were started on broad-spectrum antibiotics intravenously; 18 (47.4%) patients received one antibiotic, 10 (26.3%) received two different antibiotics, 8 (21.1%) received three different antibiotics, and two patients (5.3%) received four different antibiotics. Twenty-three (60.5%) patients received Vancomycin alone or in combination with other antibiotics. Piperacillin/Tazobactam was used in 17 (44.7%) cases and Ceftriaxone and Clindamycin were used in 10 (26.3%) and 8 (21.1%) cases respectively. Other antibiotics used included Penicillin G in 3 (7.9%) patients and Trimethoprim/sulfamethoxazole in 2 (5.3%) patients. Metronidazole, Ertapenem, and Meropenem were each used only once, in three different patients (Fig. 3 ). Upon initial presentation to the emergency department (ED), the majority of patients were in the operating room within at least 24 hours of presentation 22 (57.9%). Eleven (28.9%) patients were taken to the operating room within 48 hours and three (7.9%) patients, were in the operating room 72 or more hours after initial presentation. Two patients left the hospital, against medical advice, prior to surgical intervention. As it relates to the type of surgical procedure required for patients in this sample, 26 patients (68.4%) underwent incision and drainage and 10 (26.3%) underwent irrigation and debridement. Two patients underwent amputation of the infected hand or arm. In 26 (68.4%) cases, repeat surgical intervention was required. The most common investigations completed in the study population included wound culture 36 (94.7%), complete blood count 35 (94.6%), and a metabolic panel 34 (89.5%). Other investigations included a lactate level 23 (60.5%) and C-reactive protein 21 (55.3%). In 16 (42.1%) patients, blood cultures were obtained. Imaging was not routinely utilized for the investigation of SSTIs in this study population; ultrasound and computed tomography (CT) were completed in 6 (15.8%) and 4 (10.5%) cases, respectively. Two patients (5.2%) underwent magnetic resonance imaging (MRI). The median length of hospital stay was 6 days (IQR: 4–14.5). Eighteen (47.4%) patients were discharged to home or community, and 10 (26.3%) discharges were patient-directed (left against medical advice). Of the 10 patients who left the hospital against medical advice, 8 (80.0%) were PWID (Table 2 ). DISCUSSION Areas of increased vascularity, such as the groin and antecubital fossa, are among the most common sites of injection for intravenous drug users. 11 These findings are consistent with other studies in the literature, which found the most common sites of infection in PWID to be the antecubital fossa, arm, and hand. 12 , 13 Prior studies have typically demonstrated that females are more likely to be affected by SSTIs than males, especially in injection drug use related cases. 14 , 15 With a male-to-female ratio of 21:17 in our study population, this trend was not observed. However, the number of male and female patients in this study was roughly equal and the discrepancy with prior studies may be in part explained by the small sample size of our study. The average age of patients in our study is equally consistent with findings in prior studies of SSTIs secondary to IVDU. 2 The microbiology of SSTIs in PWID is generally predictable; Staphylococcus aureus and Streptococcus pyogenes are the most common culture isolates of SSTIs associated with IVDU. 16 – 19 In addition, one of the strongest risk factors associated with MRSA positive SSTIs is IVDU. 20 While Staphylococcus aureus is also a common culprit in SSTIs of persons who do not inject drugs, Streptococcus pyogenes is more prevalent in PWID. 21 In addition, PWIDs are more likely to present with anaerobic and polymicrobial infections as compared to those who do not inject drugs. 22 Culture results in our patient population are consistent with these findings, with the vast majority of cases isolating Streptococcus pyogenes, Staphylococcus aureus (including MRSA), and polymicrobial organisms. Knowledge of specific microbes implicated in the pathogenesis of SSTIs in PWID is essential to direct the choice of antibiotic therapy for these infections. Recent landmark trials out of the United States have found improved outcomes and higher cure rates with the combination of empiric antibiotic therapy and incision and drainage for the treatment of SSTIs. 23 , 24 Both studies selected antibiotics covering GAS, GBS, and MRSA (Trimethoprim–Sulfamethoxazole and Clindamycin). 23 , 24 Similarly, in our study, a majority of patients (60.5%) received a course of Vancomycin, a broad-spectrum antibiotic covering the most commonly implicated microbes including MSSA, MRSA, and Streptococcus species. Necrotizing fasciitis (NF) is a rapidly progressive infection of the subcutaneous fat and fascia. Although rare, NF is a life-threatening infection, with mortality rates reaching 50%. 22,23 Given this, prompt diagnosis, surgical intervention, and initiation of broad-spectrum antibiotic therapy are essential in the management of NF. In our patient population, NF was diagnosed in 7 (18.4%) patients, three of which, were known injection drug users. Streptococcus pyogenes was isolated in 6 (85.7%) of the necrotizing fasciitis cases in our study. This is consistent with previous findings in the literature demonstrating Streptococcus pyogenes as the most common cause of mono-bacterial necrotizing soft tissue infections. 25 It has been frequently reported in the literature that injection drug use is a significant risk factor for the development of necrotizing soft tissue infections. 19 , 26 , 27 There are several possible reasons for this, including the direct inosculation of bacteria from contaminated drug products or injection equipment, increased rates of Staphylococcus aureus colonization in PWID, and non-vascular injection into the skin. 19 Although IVDU appears to be a significant risk factor for the development of NF, the mortality rate of NF in PWID tends to be lower than in the non-injection drug use population. Waldron et al. found in patients diagnosed with NF, the mortality rate for PWID was 17% as compared to the overall mortality rate of 29%. 28 Similarly, Chen et al. found a mortality rate of 10% for PWID diagnosed with NF, as opposed to 21% among those who do not inject drugs. 29 These discrepancies may be explained by a higher index of clinical suspicion in PWID resulting in surgical intervention within 24 hours of presentation to the hospital. 22 , 24 Necrotizing fasciitis in PWID has also been associated with an increased risk of requiring amputation of the infected area and the development of deep vein thrombosis. 30 , 31 In our study, two patients underwent amputation; both patients had a primary diagnosis of Necrotizing fasciitis and were PWID. In addition, PWID are at increased risk for recurrent SSTIs, leading to re-admissions to hospital and additional surgical procedures. Chan et al. found that of PWID presenting with NF, 32% of these patients had a prior abscess or cellulitis. 29 Similarly, nearly one-third of patients in our study had a prior soft tissue infection requiring surgical management. In our patient cohort, the median length of hospital stay was 6 days (IQR: 4–14.5). A previous study evaluating hospital admissions amongst the PWID population in Regina, Saskatchewan found the median length of hospital stay to be 7.7 days. In addition, of the 149 patients included in that study, 30% of all admissions were due to SSTIs. They determined the average cost of stay for the PWID population to be $ 24,982 CAD, which is significantly more than the standard cost of hospital stay in the region.5 In keeping with this, several other Canadian studies found the average hospital stay for the PWID population to be greater than those without a history of substance use. 10 , 32 In the current study, 26% of all patient discharges from the hospital were patient-directed (against medical advice). Patient-directed discharge is three times more common in patients with substance use disorder compared to those without. 33 Factors such as perceived stigma from healthcare staff, uncontrolled pain, and untreated withdrawal contribute to patients leaving the hospital before the completion of treatment. 33 Leaving the hospital before the completion of treatment contributes to higher rates of readmission, negative health outcomes, and higher rates of mortality. 34 – 36 These findings underscore the importance of strategies that reduce premature patient-directed discharge and promote completion of treatment. We propose that harm reduction strategies initiated during hospital admission may reduce the rate of patients leaving the hospital before the completion of treatment. Inpatient opioid agonist therapy such as methadone, and the involvement of social supports including family and friends, are mitigating factors that may reduce the rate of patient-directed hospital discharge. 37 In one study, initiation of methadone during the patient's hospital admission was found to reduce the rate of discharge against medical advice by 50%. 37 In Saskatoon hospitals, harm reduction strategies may include the involvement of addiction medicine services and social work during the patient's hospital admission. In the community, increased access to needle syringe programs and supervised consumption sites has proven to reduce SSTIs in the PWID population. 38 This data suggests that the uptake of harm reduction strategies in hospitals and the community would greatly benefit the PWID population from a morbidity and mortality standpoint. The retrospective nature of this study poses several limitations. Firstly, of the 38 patients included in this study, 10 left against medical advice, two of which left prior to planned surgical intervention. Secondly, in comparison to other similar studies, a total of 38 patients in the current study met the inclusion criteria, making our sample size relatively small. In addition, many patients do not disclose injection drug use, due to associated stigma and other factors. Therefore, the number of patients reported to use injection drugs in this study may be underestimated. CONCLUSION This study highlights the need to address harm-reduction strategies aimed at reducing the development, and recurrence, of SSTIs in the PWID population. People who inject drugs experience a disproportionate burden of recurrent SSTIs, prolonged hospital admissions, and repeat surgical interventions. Furthermore, the increased risk of developing necrotizing fasciitis associated with injection drug use underscores the critical need for healthcare providers to maintain a high index of clinical suspicion when caring for this patient population. By implementing harm reduction strategies during patients' hospital admission, we anticipate a decrease in patient-directed discharge, facilitating the completion of treatment. In addition, by expanding access to needle syringe programs in the community, we expect a reduction in SSTIs requiring surgical intervention and hospital admission in the injection drug use population. Abbreviations IVDU – Intravenous Drug Use PWID – People Who Inject Drugs SSTI – Skin and Soft Tissue Infections NF – Necrotizing Fasciitis Declarations Ethics Approval and Consent Under the guidance of the Biomedical Research Ethics Board at the University of Saskatchewan, obtaining patient consent was waived due to it being impossible or impractical to seek individual consent given the retrospective nature of this study. All portions of this research including data collection and statistical analysis, did not involve direct or indirect patient contact. The investigators have taken the appropriate measures to ensure the protection of the personal information of the individuals included in this study. The data was collected and deidentified, and only aggregate data are published. IRB Approval Statement: The University of Saskatchewan Biomedical Research Ethics Board approved the study protocol (Bio 2875). Consent for Publication Not applicable. Availability of Data and Materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Competing Interests The authors declare that they have no competing interests. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Author Contributions Conceptualization, R.M., C.T., G.G..; methodology, R.M., C.T., G.G..; validation, R.M., C.T., G.G..; data curation, R.M.; formal analysis, E.Y.; writing—original draft preparation, E.Y., R.M., R.R.; writing—review and editing, E.Y., R.M., R.R., C.T., G.G.; supervision, C.T.; project administration, E.Y., R.M., R.R., C.T., G.G.; All authors have read and agreed to the published version of the manuscript. Acknowledgements Not applicable. References Jacka B, Larney S, Degenhardt L, et al. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. Am J Public Health. 2020;110(1):45-50. doi:10.2105/AJPH.2019.305379 Tsybina P, Kassir S, Clark M, Skinner S. Hospital admissions and mortality due to complications of injection drug use in two hospitals in Regina, Canada: retrospective chart review. Harm Reduct J. 2021;18(1):44. doi:10.1186/s12954-021-00492-6 Canada PHA of. HIV in Canada, Surveillance Report to December 31, 2020. Published July 25, 2022. Accessed December 15, 2023. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-canada-surveillance-report-december-31-2020.html Hepatitis C in Canada: 2020 surveillance data update. Published March 3, 2023. Accessed December 15, 2023. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hepatitis-c-canada-2020-surveillance-data-update.html Hrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B. Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage. Harm Reduct J. 2022;19(1):41. doi:10.1186/s12954-022-00624-6 Lavender TW, McCarron B. Acute infections in intravenous drug users. Clin Med. 2013;13(5):511-513. doi:10.7861/clinmedicine.13-5-511 Binswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO. Drug Users Seeking Emergency Care for Soft Tissue Infection at High Risk for Subsequent Hospitalization and Death. J Stud Alcohol Drugs. 2008;69(6):924-932. doi:10.15288/jsad.2008.69.924 Kerr T, Wood E, Grafstein E, et al. High Rates of Primary Care and Emergency Department Use Among Injection Drug Users in Vancouver. J Public Health. 2005;27(1):62-66. doi:10.1093/pubmed/fdh189 Takahashi TA, Baernstein A, Binswanger I, Bradley K, Merrill JO. Predictors of Hospitalization for Injection Drug Users Seeking Care for Soft Tissue Infections. J Gen Intern Med. 2007;22(3):382-388. doi:10.1007/s11606-006-0079-y Fung JST, Ali E, Xiao T, Borkovich R. Impact of Substance Use Disorder on Healthcare Utilization in Patients Admitted with Severe Infections: A Retrospective Study. Can J Gen Intern Med. 2023;18(1):28-36. Chotai N, Gallagher K, Kieffer WKM, Rogers BA, Ricketts DM. A comparative analysis of the patient characteristics and cost of managing intravenous drug users (IVDU) with soft tissue abscesses with non-IVDU. The Surgeon. 2016;14(1):13-17. doi:10.1016/j.surge.2014.08.003 Buckland A, Barton R, McCombe D. Upper limb morbidity as a direct consequence of intravenous drug abuse. Hand Surg. 2008;13(02):73-78. doi:10.1142/S0218810408003931 Hope V, Kimber J, Vickerman P, Hickman M, Ncube F. Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis. 2008;8(1):120. doi:10.1186/1471-2334-8-120 Smith ME, Robinowitz N, Chaulk P, Johnson KE. High Rates of Abscesses and Chronic Wounds in Community-Recruited Injection Drug Users and Associated Risk Factors. J Addict Med. 2015;9(2):87-93. doi:10.1097/ADM.0000000000000093 Baltes A, Akhtar W, Birstler J, et al. Predictors of skin and soft tissue infections among sample of rural residents who inject drugs. Harm Reduct J. 2020;17(1):96. doi:10.1186/s12954-020-00447-3 Henriksen BM, Albrektsen SB, Simper LB, Gutschik E. Soft tissue infections from drug abuse: A clinical and microbiological review of 145 cases. Acta Orthop Scand. 1994;65(6):625-628. doi:10.3109/17453679408994618 Schnall SB, Holtom PD, Lilley JC. Abscesses secondary to parenteral abuse of drugs. A study of demographic and bacteriological characteristics.: J Bone Jt Surg. 1994;76(10):1526-1530. doi:10.2106/00004623-199410000-00012 Simmen HP, Giovanoli P, Battaglia H, Wüst J, Meyer VE. Soft Tissue Infections of the Upper Extremities with Special Consideration of Abscesses in Parenteral Drug Abusers: A prospective study. J Hand Surg. 1995;20(6):797-800. doi:10.1016/S0266-7681(95)80050-6 Chambers HF. Skin and Soft Tissue Infections in Persons Who Inject Drugs. Infect Dis Clin North Am. 2021;35(1):169-181. doi:10.1016/j.idc.2020.10.006 Stenstrom R, Grafstein E, Romney M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department. CJEM. 2009;11(05):430-438. doi:10.1017/S1481803500011623 Jenkins TC, Knepper BC, Jason Moore S, et al. Microbiology and Initial Antibiotic Therapy for Injection Drug Users and Non-Injection Drug Users with Cutaneous Abscesses in the Era of Community-associated Methicillin-resistant Staphylococcus aureus. Merchant R, ed. Acad Emerg Med. 2015;22(8):993-997. doi:10.1111/acem.12727 Summanen PH, Talan DA, Strong C, et al. Bacteriology of Skin and Soft-Tissue Infections: Comparison of Infections in Intravenous Drug Users and Individuals with No History of Intravenous Drug Use. Clin Infect Dis. 1995;20(Supplement_2):S279-S282. doi:10.1093/clinids/20.Supplement_2.S279 Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med. 2016;374(9):823-832. doi:10.1056/NEJMoa1507476 Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med. 2017;376(26):2545-2555. doi:10.1056/NEJMoa1607033 McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of Mortality for Necrotizing Soft-Tissue Infections: Ann Surg. 1995;221(5):558-565. doi:10.1097/00000658-199505000-00013 Narayan M, Juprasert J, Finn C, Barie PS. Recurrent Necrotizing Soft Tissue Infections with Atypical Pathogens after Injection Drug Abuse: Another Manifestation of the Opioid Crisis. Surg Infect. 2020;21(5):411-415. doi:10.1089/sur.2019.187 Saeed K, Esposito S, Gould I, et al. Hot topics in necrotising skin and soft tissue infections. Int J Antimicrob Agents. 2018;52(1):1-10. doi:10.1016/j.ijantimicag.2018.02.012 Waldron C, Solon JG, O’Gorman J, Humphreys H, Burke JP, McNamara DA. Necrotizing fasciitis: The need for urgent surgical intervention and the impact of intravenous drug use. The Surgeon. 2015;13(4):194-199. doi:10.1016/j.surge.2014.01.005 Chen JL, Fullerton KE, Flynn NM. Necrotizing Fasciitis Associated with Injection Drug Use. Clin Infect Dis. 2001;33(1):6-15. doi:10.1086/320874 Mittapalli D, Velineni R, Rae N, Howd A, Suttie SA. Necrotizing Soft Tissue Infections in Intravenous Drug Users: A Vascular Surgical Emergency. Eur J Vasc Endovasc Surg. 2015;49(5):593-599. doi:10.1016/j.ejvs.2015.02.002 Ginting KE, Caparelli M, Kundu N. Necrotizing Soft Tissue Infection After Intravenous Drug Injection: A Multidisciplinary Approach to Surgical Management at a Community Hospital. Am Surg. 2020;86(9):1215-1217. doi:10.1177/0003134820933596 Sardiwalla Y, Nachmani O, Price E, Huynh M, Coroneos C, McRae M. Upper Extremity Infection Related to Intravenous Drug Use: Considering the True Cost of the COVID-19 Pandemic and Lockdown. HAND. 2023;18(6):999-1004. doi:10.1177/15589447221077377 Simon R, Snow R, Wakeman S. Understanding why Patients with Substance use Disorders Leave the Hospital against Medical Advice: A Qualitative Study. Subst Abuse. 2020;41(4):519-525. doi:10.1080/08897077.2019.1671942 Weingart SN, Davis RB, Phillips RS. Patients discharged against medical advice from a general medicine service. J Gen Intern Med. 1998;13(8):568-571. doi:10.1046/j.1525-1497.1998.00169.x Hwang SW, Li J, Gupta R, Chien V, Martin RE. What happens to patients who leave hospital against medical advice? CMAJ Can Med Assoc J J Assoc Medicale Can. 2003;168(4):417-420. Garland A, Ramsey CD, Fransoo R, et al. Rates of readmission and death associated with leaving hospital against medical advice: a population-based study. Can Med Assoc J. 2013;185(14):1207-1214. doi:10.1503/cmaj.130029 Chan ACH, Palepu A, Guh DP, et al. HIV-Positive Injection Drug Users Who Leave the Hospital Against Medical Advice: The Mitigating Role of Methadone and Social Support. JAIDS J Acquir Immune Defic Syndr. 2004;35(1):56-59. doi:10.1097/00126334-200401010-00008 Dunleavy K, Munro A, Roy K, et al. Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. Drug Alcohol Depend. 2017;174:91-97. doi:10.1016/j.drugalcdep.2017.01.020 Tables Table 1: Patient Characteristics Characteristic Data Number of patients 38 Patient age (years), median, [interquartile range] 34 [28 - 49] Patient sex, n (%) Male 21 (55.3) Female 17 (44.7) Location of infection, n (%) Unilateral hand 22 (57.9) Unilateral upper arm 11 (28.9) Bilateral hands 3 (7.9) Unilateral wrist 2 (5.3) Bilateral upper arm 0 (0) Bilateral wrists 0 (0) Comorbidities, n (%) Cigarette smoking 31 (81.6) Intravenous drug use 19 (50) Type 2 diabetes mellitus 7 (18.4) End-stage renal disease 1 (2.6) Taking immunosuppressive medication 1 (2.6) Past medical history, n (%) Previous soft tissue infection requiring surgical management 10 (26.3) Table 2: Course in Hospital Characteristic Data Length of stay, median [interquartile range], days 6 [4-14.5] Time from presentation to operation, n (%) Within 24 hours 22 (57.9) 24 – 48 hours 11 (28.9) Over 48 hours 3 (7.9) Type of procedure, n (%) Incision and drainage 26 (68.4) Irrigation and debridement 10 (26.3) Amputation 2 (5.3) Imaging investigations, n (%) US 6 (15.8) CT 4 (10.5) MRI 2 (5.3) Laboratory investigations, n (%) Wound culture 36 (94.7) CBC 35 (94.6) Metabolic panel 34 (89.5) Lactate 23 (60.5) CRP 21 (55.3) Blood culture 16 (42.1) LFT 16 (42.1) CK 13 (34.2) Disposition, n (%) Home or community 18 (47.4) Left against medical advice 10 (26.3) Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4004749","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":276327799,"identity":"fb2a89cd-7ab2-455e-b978-51fe5ad962b9","order_by":0,"name":"Emma J Yanko","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA3ElEQVRIiWNgGAWjYHACZhh9AEQakKKFLYFkLTwGxGkxOH72sMEHBpto3fYz3yR/1NQZM7AffoBfy5m85MQZDGm5287kbpPmOXbYjIEnDb9NBgdyjA/zMBzO3XYAqIWB7YANgwQBxxmcfwPS8j932/k3zyR//KsDamH/gF/LjRzjZB4GoBU3ctgkeNuYzRgkePDbInnjjbHhDINkoJZnxta8fYeN2XhyCvBq4TufYyzxocIO6LDkhzd/fKsz7Gc/vgGvFoUDYOchibDhVQ8E8g2EVIyCUTAKRsEoAADzLkXSHa6/mgAAAABJRU5ErkJggg==","orcid":"","institution":"University of Saskatchewan","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Emma","middleName":"J","lastName":"Yanko","suffix":""},{"id":276327800,"identity":"60186a8c-9f83-438a-af67-d5d41c66a1bf","order_by":1,"name":"Rachel L Miller","email":"","orcid":"","institution":"University of Saskatchewan","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rachel","middleName":"L","lastName":"Miller","suffix":""},{"id":276327801,"identity":"e5971d7a-2645-4f72-aeec-c2602098a774","order_by":2,"name":"Retaj H Ramadan","email":"","orcid":"","institution":"University of Saskatchewan","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Retaj","middleName":"H","lastName":"Ramadan","suffix":""},{"id":276327802,"identity":"6311910b-46c7-4588-8abb-04bd46d06f34","order_by":3,"name":"Gary Groot","email":"","orcid":"","institution":"University of Saskatchewan","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Gary","middleName":"","lastName":"Groot","suffix":""},{"id":276327803,"identity":"b0888078-1626-43c5-8122-9fab8cd1fbf5","order_by":4,"name":"Chris Thomson","email":"","orcid":"","institution":"University of Saskatchewan","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Chris","middleName":"","lastName":"Thomson","suffix":""}],"badges":[],"createdAt":"2024-03-01 22:37:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4004749/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4004749/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":52105548,"identity":"8f61094d-eaa9-42a5-9f02-de08bd4f1124","added_by":"auto","created_at":"2024-03-06 19:28:28","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":606685,"visible":true,"origin":"","legend":"\u003cp\u003eA figure demonstrating the type of organisms isolated from tissue culture in Necrotizing Fasciitis cases.\u003c/p\u003e","description":"","filename":"Figure1SSTI.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4004749/v1/10943e975d989d6df8fa8b67.jpg"},{"id":52105547,"identity":"3871bc18-947d-45f8-ba0f-b722d833c527","added_by":"auto","created_at":"2024-03-06 19:28:28","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":665829,"visible":true,"origin":"","legend":"\u003cp\u003eA figure demonstrating the type of organisms isolated from all tissue cultures, including necrotizing and non-necrotizing skin and soft tissue infections.\u003c/p\u003e","description":"","filename":"Figure2SSTI.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4004749/v1/acd70d865d65a7b70f8e1d5e.jpg"},{"id":52105546,"identity":"64f8459b-84dd-4c5a-9990-8f4054fdf433","added_by":"auto","created_at":"2024-03-06 19:28:28","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":679356,"visible":true,"origin":"","legend":"\u003cp\u003eA figure demonstrating the type of antibiotic therapy used to treat skin and soft tissue infections.\u003c/p\u003e","description":"","filename":"Figure3SSTI.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4004749/v1/a950765f42501a8873518637.jpg"},{"id":52536077,"identity":"14ffcb67-0aa8-416a-a62c-9d6a865afb4a","added_by":"auto","created_at":"2024-03-12 16:32:59","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":387604,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4004749/v1/2ee5db83-e856-4d92-aaf4-1dd75f1117ba.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Epidemiology of upper limb skin and soft tissue infections requiring surgical intervention in Saskatoon, Canada: A retrospective chart review","fulltext":[{"header":"BACKGROUND","content":"\u003cp\u003eIntravenous drug use (IVDU) is associated with significant morbidity and mortality. In 2016, the national population prevalence of people who inject drugs (PWID) in Canada was reported to be 0.70 per 100 persons aged 15 to 64. In Saskatchewan, however, the provincial population prevalence was much greater at 0.97 per 100 persons aged 15 to 64 years.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e IVDU is the most common risk factor for the acquisition of both hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in Saskatchewan. Consequently, Saskatchewan has a significantly higher incidence of new HCV and HIV diagnoses compared to the national rate.\u003csup\u003e\u003cspan additionalcitationids=\"CR3\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003ePeople who inject drugs are at increased risk for the development of bacterial, fungal, and blood-borne infections; often spread via the use of contaminated injection drug supplies, unsanitary conditions, and low vaccination rates in these populations.\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e Skin and soft tissue infections (SSTIs) exemplify the infections that contribute to morbidity and mortality in PWID.\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e Studies in both Canada and the United States have found that SSTIs represent a leading cause of hospitalization and engagement with the healthcare system in PWID.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e The management of SSTIs often requires long hospital admissions, and surgical interventions, resulting in high healthcare associated costs. In addition, several studies report the average cost of hospitalization in PWID to be greater than in patients who do not use injection drugs.\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eThere is an urgent need to better understand and recognize the characteristics of patients admitted to hospitals with SSTIs in Canada. This study aimed to describe the epidemiology, hospital course, and prevalence of injection drug use in patients with a primary diagnosis of upper limb SSTIs requiring surgical intervention at St. Paul\u0026rsquo;s Hospital and Royal University Hospital (Saskatoon, Canada) between January 1 and December 31, 2020. Additionally, we sought to describe harm reduction strategies aimed at preventing the development of SSTIs in the PWID population.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cp\u003e \u003cb\u003eStudy Design\u003c/b\u003e \u003c/p\u003e \u003cp\u003e This retrospective chart review involved patients with upper limb skin and soft tissue infection who were admitted to St. Paul\u0026rsquo;s Hospital or Royal University Hospital (Saskatoon, SK, CA) between January 1, 2020, and December 31, 2020. Patients were excluded if the soft tissue infection did not involve the upper limb (hand to shoulder) or did not require surgical intervention. The University of Saskatchewan Biomedical Research Ethics Board approved the study protocol (Bio 2875). International Classification of Disease codes (ICD) were used to identify eligible patients from the Saskatchewan Health Authority medical records database.\u003c/p\u003e \u003cp\u003e \u003cb\u003eData Collection\u003c/b\u003e \u003c/p\u003e \u003cp\u003eA pre-determined data abstraction sheet was used for data collection and one researcher (RM) collected the data. Data was organized within 10 predetermined categories: patient demographics (age, gender, smoking, injection drug use, comorbidities), location of infection, prior SSTIs requiring surgical intervention, choice of antibiotic, mode of antibiotic, culture results, time from initial presentation to procedure, length of stay, repeat procedures, and hospital discharge.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eDescriptive statistics were performed to summarize the characteristics of the studied population including demographics, course in hospital, antibiotic treatment, culture results, and infection classification. Categorical data was analyzed as frequency and the corresponding proportion using Microsoft Excel.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003eA total of 132 patients were identified. Of these, 94 patients were excluded due to the anatomic location of the SSTI or lack of surgical intervention. Of the 38 patients included in the study, the median patient age was 34 years (IQR: 28 to 49 years) and the male: female ratio was 21:17. Among these, 31 (81.6%) smoked cigarettes and 19 (50.0%) used intravenous drugs. The most common comorbidity reported was type 2 diabetes mellitus in 7 (18.4%) patients. One patient was noted to be taking immunosuppressive medication and one patient had end-stage renal disease. Ten (26.3%) patients had a prior soft tissue infection requiring surgical management.\u003c/p\u003e\n\u003cp\u003eA majority of the skin and soft tissue infections assessed in this study were unilateral infections; either involving the hand 22 (57.9%) or the upper arm 11 (28.9%). Three cases involved the bilateral hands (7.9%) and two cases involved the unilateral wrist (5.3%). There were no bilateral upper arm or bilateral wrist infections diagnosed in the study population (Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e\n\u003cp\u003eNecrotizing fasciitis was diagnosed in 7 (18.4%) patients in this sample and was most commonly associated with Streptococcus pyogenes (GAS) (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). The most common microbe cultured in all assessed SSTIs was GAS 17 (44.7%). Methicillin-resistant Staphylococcus aureus (MRSA) was cultured in 5 (13.2%) patients and Methicillin-susceptible Staphylococcus aureus (MSSA) in 4 (10.5%) cases. Four of the patients (11%) had culture-negative results and 6 (15.7%) grew multiple organisms; of these, four grew both Streptococcus pyogenes and Streptococcus agalactiae (GBS) (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003cp\u003eAll patients were started on broad-spectrum antibiotics intravenously; 18 (47.4%) patients received one antibiotic, 10 (26.3%) received two different antibiotics, 8 (21.1%) received three different antibiotics, and two patients (5.3%) received four different antibiotics. Twenty-three (60.5%) patients received Vancomycin alone or in combination with other antibiotics. Piperacillin/Tazobactam was used in 17 (44.7%) cases and Ceftriaxone and Clindamycin were used in 10 (26.3%) and 8 (21.1%) cases respectively. Other antibiotics used included Penicillin G in 3 (7.9%) patients and Trimethoprim/sulfamethoxazole in 2 (5.3%) patients. Metronidazole, Ertapenem, and Meropenem were each used only once, in three different patients (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003cp\u003eUpon initial presentation to the emergency department (ED), the majority of patients were in the operating room within at least 24 hours of presentation 22 (57.9%). Eleven (28.9%) patients were taken to the operating room within 48 hours and three (7.9%) patients, were in the operating room 72 or more hours after initial presentation. Two patients left the hospital, against medical advice, prior to surgical intervention. As it relates to the type of surgical procedure required for patients in this sample, 26 patients (68.4%) underwent incision and drainage and 10 (26.3%) underwent irrigation and debridement. Two patients underwent amputation of the infected hand or arm. In 26 (68.4%) cases, repeat surgical intervention was required.\u003c/p\u003e\n\u003cp\u003eThe most common investigations completed in the study population included wound culture 36 (94.7%), complete blood count 35 (94.6%), and a metabolic panel 34 (89.5%). Other investigations included a lactate level 23 (60.5%) and C-reactive protein 21 (55.3%). In 16 (42.1%) patients, blood cultures were obtained. Imaging was not routinely utilized for the investigation of SSTIs in this study population; ultrasound and computed tomography (CT) were completed in 6 (15.8%) and 4 (10.5%) cases, respectively. Two patients (5.2%) underwent magnetic resonance imaging (MRI). The median length of hospital stay was 6 days (IQR: 4\u0026ndash;14.5). Eighteen (47.4%) patients were discharged to home or community, and 10 (26.3%) discharges were patient-directed (left against medical advice). Of the 10 patients who left the hospital against medical advice, 8 (80.0%) were PWID (Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eAreas of increased vascularity, such as the groin and antecubital fossa, are among the most common sites of injection for intravenous drug users.\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e These findings are consistent with other studies in the literature, which found the most common sites of infection in PWID to be the antecubital fossa, arm, and hand.\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003ePrior studies have typically demonstrated that females are more likely to be affected by SSTIs than males, especially in injection drug use related cases.\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e With a male-to-female ratio of 21:17 in our study population, this trend was not observed. However, the number of male and female patients in this study was roughly equal and the discrepancy with prior studies may be in part explained by the small sample size of our study. The average age of patients in our study is equally consistent with findings in prior studies of SSTIs secondary to IVDU.\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eThe microbiology of SSTIs in PWID is generally predictable; Staphylococcus aureus and Streptococcus pyogenes are the most common culture isolates of SSTIs associated with IVDU.\u003csup\u003e\u003cspan additionalcitationids=\"CR17 CR18\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e In addition, one of the strongest risk factors associated with MRSA positive SSTIs is IVDU.\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eWhile Staphylococcus aureus is also a common culprit in SSTIs of persons who do not inject drugs, Streptococcus pyogenes is more prevalent in PWID.\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e In addition, PWIDs are more likely to present with anaerobic and polymicrobial infections as compared to those who do not inject drugs.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e Culture results in our patient population are consistent with these findings, with the vast majority of cases isolating Streptococcus pyogenes, Staphylococcus aureus (including MRSA), and polymicrobial organisms.\u003c/p\u003e \u003cp\u003eKnowledge of specific microbes implicated in the pathogenesis of SSTIs in PWID is essential to direct the choice of antibiotic therapy for these infections. Recent landmark trials out of the United States have found improved outcomes and higher cure rates with the combination of empiric antibiotic therapy and incision and drainage for the treatment of SSTIs.\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e Both studies selected antibiotics covering GAS, GBS, and MRSA (Trimethoprim\u0026ndash;Sulfamethoxazole and Clindamycin).\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e Similarly, in our study, a majority of patients (60.5%) received a course of Vancomycin, a broad-spectrum antibiotic covering the most commonly implicated microbes including MSSA, MRSA, and Streptococcus species.\u003c/p\u003e \u003cp\u003eNecrotizing fasciitis (NF) is a rapidly progressive infection of the subcutaneous fat and fascia. Although rare, NF is a life-threatening infection, with mortality rates reaching 50%.\u003csup\u003e22,23\u003c/sup\u003e Given this, prompt diagnosis, surgical intervention, and initiation of broad-spectrum antibiotic therapy are essential in the management of NF. In our patient population, NF was diagnosed in 7 (18.4%) patients, three of which, were known injection drug users. Streptococcus pyogenes was isolated in 6 (85.7%) of the necrotizing fasciitis cases in our study. This is consistent with previous findings in the literature demonstrating Streptococcus pyogenes as the most common cause of mono-bacterial necrotizing soft tissue infections.\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eIt has been frequently reported in the literature that injection drug use is a significant risk factor for the development of necrotizing soft tissue infections.\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e,\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e There are several possible reasons for this, including the direct inosculation of bacteria from contaminated drug products or injection equipment, increased rates of Staphylococcus aureus colonization in PWID, and non-vascular injection into the skin.\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAlthough IVDU appears to be a significant risk factor for the development of NF, the mortality rate of NF in PWID tends to be lower than in the non-injection drug use population. Waldron et al. found in patients diagnosed with NF, the mortality rate for PWID was 17% as compared to the overall mortality rate of 29%.\u003csup\u003e28\u003c/sup\u003e Similarly, Chen et al. found a mortality rate of 10% for PWID diagnosed with NF, as opposed to 21% among those who do not inject drugs.\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e These discrepancies may be explained by a higher index of clinical suspicion in PWID resulting in surgical intervention within 24 hours of presentation to the hospital. \u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eNecrotizing fasciitis in PWID has also been associated with an increased risk of requiring amputation of the infected area and the development of deep vein thrombosis.\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e In our study, two patients underwent amputation; both patients had a primary diagnosis of Necrotizing fasciitis and were PWID. In addition, PWID are at increased risk for recurrent SSTIs, leading to re-admissions to hospital and additional surgical procedures. Chan et al. found that of PWID presenting with NF, 32% of these patients had a prior abscess or cellulitis.\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e Similarly, nearly one-third of patients in our study had a prior soft tissue infection requiring surgical management.\u003c/p\u003e \u003cp\u003eIn our patient cohort, the median length of hospital stay was 6 days (IQR: 4\u0026ndash;14.5). A previous study evaluating hospital admissions amongst the PWID population in Regina, Saskatchewan found the median length of hospital stay to be 7.7 days. In addition, of the 149 patients included in that study, 30% of all admissions were due to SSTIs. They determined the average cost of stay for the PWID population to be \u003cspan\u003e$\u003c/span\u003e24,982 CAD, which is significantly more than the standard cost of hospital stay in the region.5 In keeping with this, several other Canadian studies found the average hospital stay for the PWID population to be greater than those without a history of substance use.\u003csup\u003e \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e \u003c/sup\u003e \u003c/p\u003e \u003cp\u003eIn the current study, 26% of all patient discharges from the hospital were patient-directed (against medical advice). Patient-directed discharge is three times more common in patients with substance use disorder compared to those without.\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e Factors such as perceived stigma from healthcare staff, uncontrolled pain, and untreated withdrawal contribute to patients leaving the hospital before the completion of treatment.\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e Leaving the hospital before the completion of treatment contributes to higher rates of readmission, negative health outcomes, and higher rates of mortality.\u003csup\u003e\u003cspan additionalcitationids=\"CR35\" citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e These findings underscore the importance of strategies that reduce premature patient-directed discharge and promote completion of treatment.\u003c/p\u003e \u003cp\u003eWe propose that harm reduction strategies initiated during hospital admission may reduce the rate of patients leaving the hospital before the completion of treatment. Inpatient opioid agonist therapy such as methadone, and the involvement of social supports including family and friends, are mitigating factors that may reduce the rate of patient-directed hospital discharge.\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e In one study, initiation of methadone during the patient's hospital admission was found to reduce the rate of discharge against medical advice by 50%.\u003csup\u003e37\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eIn Saskatoon hospitals, harm reduction strategies may include the involvement of addiction medicine services and social work during the patient's hospital admission. In the community, increased access to needle syringe programs and supervised consumption sites has proven to reduce SSTIs in the PWID population.\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e This data suggests that the uptake of harm reduction strategies in hospitals and the community would greatly benefit the PWID population from a morbidity and mortality standpoint.\u003c/p\u003e \u003cp\u003eThe retrospective nature of this study poses several limitations. Firstly, of the 38 patients included in this study, 10 left against medical advice, two of which left prior to planned surgical intervention. Secondly, in comparison to other similar studies, a total of 38 patients in the current study met the inclusion criteria, making our sample size relatively small. In addition, many patients do not disclose injection drug use, due to associated stigma and other factors. Therefore, the number of patients reported to use injection drugs in this study may be underestimated.\u003c/p\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003eThis study highlights the need to address harm-reduction strategies aimed at reducing the development, and recurrence, of SSTIs in the PWID population. People who inject drugs experience a disproportionate burden of recurrent SSTIs, prolonged hospital admissions, and repeat surgical interventions. Furthermore, the increased risk of developing necrotizing fasciitis associated with injection drug use underscores the critical need for healthcare providers to maintain a high index of clinical suspicion when caring for this patient population. By implementing harm reduction strategies during patients' hospital admission, we anticipate a decrease in patient-directed discharge, facilitating the completion of treatment. In addition, by expanding access to needle syringe programs in the community, we expect a reduction in SSTIs requiring surgical intervention and hospital admission in the injection drug use population.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eIVDU \u0026ndash; Intravenous Drug Use\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePWID \u0026ndash; People Who Inject Drugs\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSSTI \u0026ndash; Skin and Soft Tissue Infections\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNF \u0026ndash; Necrotizing Fasciitis\u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics Approval and Consent\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUnder the guidance of the Biomedical Research Ethics Board at the University of Saskatchewan, obtaining patient consent was waived due to it being impossible or impractical to seek individual consent given the retrospective nature of this study. All portions of this research including data collection and statistical analysis, did not involve direct or indirect patient contact. The investigators have taken the appropriate measures to ensure the protection of the personal information of the individuals included in this study. The data was collected and deidentified, and only aggregate data are published.\u003c/p\u003e\n\u003cp\u003eIRB Approval Statement: The University of Saskatchewan Biomedical Research Ethics Board approved the study protocol (Bio 2875).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for Publication\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of Data and Materials\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contributions\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConceptualization, R.M., C.T., G.G..; methodology, R.M., C.T., G.G..; validation, R.M., C.T., G.G..; data curation, R.M.; formal analysis, E.Y.; writing—original draft preparation, E.Y., R.M., R.R.; writing—review and editing, E.Y., R.M., R.R., C.T., G.G.; supervision, C.T.; project administration, E.Y., R.M., R.R., C.T., G.G.; All authors have read and agreed to the published version of the manuscript.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eJacka B, Larney S, Degenhardt L, et al. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. Am J Public Health. 2020;110(1):45-50. doi:10.2105/AJPH.2019.305379\u003c/li\u003e\n\u003cli\u003eTsybina P, Kassir S, Clark M, Skinner S. Hospital admissions and mortality due to complications of injection drug use in two hospitals in Regina, Canada: retrospective chart review. Harm Reduct J. 2021;18(1):44. doi:10.1186/s12954-021-00492-6\u003c/li\u003e\n\u003cli\u003eCanada PHA of. HIV in Canada, Surveillance Report to December 31, 2020. Published July 25, 2022. Accessed December 15, 2023. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-canada-surveillance-report-december-31-2020.html\u003c/li\u003e\n\u003cli\u003eHepatitis C in Canada: 2020 surveillance data update. Published March 3, 2023. Accessed December 15, 2023. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hepatitis-c-canada-2020-surveillance-data-update.html\u003c/li\u003e\n\u003cli\u003eHrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B. Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage. Harm Reduct J. 2022;19(1):41. doi:10.1186/s12954-022-00624-6\u003c/li\u003e\n\u003cli\u003eLavender TW, McCarron B. Acute infections in intravenous drug users. Clin Med. 2013;13(5):511-513. doi:10.7861/clinmedicine.13-5-511\u003c/li\u003e\n\u003cli\u003eBinswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO. Drug Users Seeking Emergency Care for Soft Tissue Infection at High Risk for Subsequent Hospitalization and Death. J Stud Alcohol Drugs. 2008;69(6):924-932. doi:10.15288/jsad.2008.69.924\u003c/li\u003e\n\u003cli\u003eKerr T, Wood E, Grafstein E, et al. High Rates of Primary Care and Emergency Department Use Among Injection Drug Users in Vancouver. J Public Health. 2005;27(1):62-66. doi:10.1093/pubmed/fdh189\u003c/li\u003e\n\u003cli\u003eTakahashi TA, Baernstein A, Binswanger I, Bradley K, Merrill JO. Predictors of Hospitalization for Injection Drug Users Seeking Care for Soft Tissue Infections. J Gen Intern Med. 2007;22(3):382-388. doi:10.1007/s11606-006-0079-y\u003c/li\u003e\n\u003cli\u003eFung JST, Ali E, Xiao T, Borkovich R. Impact of Substance Use Disorder on Healthcare Utilization in Patients Admitted with Severe Infections: A Retrospective Study. Can J Gen Intern Med. 2023;18(1):28-36.\u003c/li\u003e\n\u003cli\u003eChotai N, Gallagher K, Kieffer WKM, Rogers BA, Ricketts DM. A comparative analysis of the patient characteristics and cost of managing intravenous drug users (IVDU) with soft tissue abscesses with non-IVDU. The Surgeon. 2016;14(1):13-17. doi:10.1016/j.surge.2014.08.003\u003c/li\u003e\n\u003cli\u003eBuckland A, Barton R, McCombe D. Upper limb morbidity as a direct consequence of intravenous drug abuse. Hand Surg. 2008;13(02):73-78. doi:10.1142/S0218810408003931\u003c/li\u003e\n\u003cli\u003eHope V, Kimber J, Vickerman P, Hickman M, Ncube F. Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis. 2008;8(1):120. doi:10.1186/1471-2334-8-120\u003c/li\u003e\n\u003cli\u003eSmith ME, Robinowitz N, Chaulk P, Johnson KE. High Rates of Abscesses and Chronic Wounds in Community-Recruited Injection Drug Users and Associated Risk Factors. J Addict Med. 2015;9(2):87-93. doi:10.1097/ADM.0000000000000093\u003c/li\u003e\n\u003cli\u003eBaltes A, Akhtar W, Birstler J, et al. Predictors of skin and soft tissue infections among sample of rural residents who inject drugs. Harm Reduct J. 2020;17(1):96. doi:10.1186/s12954-020-00447-3\u003c/li\u003e\n\u003cli\u003eHenriksen BM, Albrektsen SB, Simper LB, Gutschik E. Soft tissue infections from drug abuse: A clinical and microbiological review of 145 cases. Acta Orthop Scand. 1994;65(6):625-628. doi:10.3109/17453679408994618\u003c/li\u003e\n\u003cli\u003eSchnall SB, Holtom PD, Lilley JC. Abscesses secondary to parenteral abuse of drugs. A study of demographic and bacteriological characteristics.: J Bone Jt Surg. 1994;76(10):1526-1530. doi:10.2106/00004623-199410000-00012\u003c/li\u003e\n\u003cli\u003eSimmen HP, Giovanoli P, Battaglia H, W\u0026uuml;st J, Meyer VE. Soft Tissue Infections of the Upper Extremities with Special Consideration of Abscesses in Parenteral Drug Abusers: A prospective study. J Hand Surg. 1995;20(6):797-800. doi:10.1016/S0266-7681(95)80050-6\u003c/li\u003e\n\u003cli\u003eChambers HF. Skin and Soft Tissue Infections in Persons Who Inject Drugs. Infect Dis Clin North Am. 2021;35(1):169-181. doi:10.1016/j.idc.2020.10.006\u003c/li\u003e\n\u003cli\u003eStenstrom R, Grafstein E, Romney M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department. CJEM. 2009;11(05):430-438. doi:10.1017/S1481803500011623\u003c/li\u003e\n\u003cli\u003eJenkins TC, Knepper BC, Jason Moore S, et al. Microbiology and Initial Antibiotic Therapy for Injection Drug Users and Non-Injection Drug Users with Cutaneous Abscesses in the Era of Community-associated Methicillin-resistant Staphylococcus aureus. Merchant R, ed. Acad Emerg Med. 2015;22(8):993-997. doi:10.1111/acem.12727\u003c/li\u003e\n\u003cli\u003eSummanen PH, Talan DA, Strong C, et al. Bacteriology of Skin and Soft-Tissue Infections: Comparison of Infections in Intravenous Drug Users and Individuals with No History of Intravenous Drug Use. Clin Infect Dis. 1995;20(Supplement_2):S279-S282. doi:10.1093/clinids/20.Supplement_2.S279\u003c/li\u003e\n\u003cli\u003eTalan DA, Mower WR, Krishnadasan A, et al. Trimethoprim\u0026ndash;Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med. 2016;374(9):823-832. doi:10.1056/NEJMoa1507476\u003c/li\u003e\n\u003cli\u003eDaum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med. 2017;376(26):2545-2555. doi:10.1056/NEJMoa1607033\u003c/li\u003e\n\u003cli\u003eMcHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of Mortality for Necrotizing Soft-Tissue Infections: Ann Surg. 1995;221(5):558-565. doi:10.1097/00000658-199505000-00013\u003c/li\u003e\n\u003cli\u003eNarayan M, Juprasert J, Finn C, Barie PS. Recurrent Necrotizing Soft Tissue Infections with Atypical Pathogens after Injection Drug Abuse: Another Manifestation of the Opioid Crisis. Surg Infect. 2020;21(5):411-415. doi:10.1089/sur.2019.187\u003c/li\u003e\n\u003cli\u003eSaeed K, Esposito S, Gould I, et al. Hot topics in necrotising skin and soft tissue infections. Int J Antimicrob Agents. 2018;52(1):1-10. doi:10.1016/j.ijantimicag.2018.02.012\u003c/li\u003e\n\u003cli\u003eWaldron C, Solon JG, O\u0026rsquo;Gorman J, Humphreys H, Burke JP, McNamara DA. Necrotizing fasciitis: The need for urgent surgical intervention and the impact of intravenous drug use. The Surgeon. 2015;13(4):194-199. doi:10.1016/j.surge.2014.01.005\u003c/li\u003e\n\u003cli\u003eChen JL, Fullerton KE, Flynn NM. Necrotizing Fasciitis Associated with Injection Drug Use. Clin Infect Dis. 2001;33(1):6-15. doi:10.1086/320874\u003c/li\u003e\n\u003cli\u003eMittapalli D, Velineni R, Rae N, Howd A, Suttie SA. Necrotizing Soft Tissue Infections in Intravenous Drug Users: A Vascular Surgical Emergency. Eur J Vasc Endovasc Surg. 2015;49(5):593-599. doi:10.1016/j.ejvs.2015.02.002\u003c/li\u003e\n\u003cli\u003eGinting KE, Caparelli M, Kundu N. Necrotizing Soft Tissue Infection After Intravenous Drug Injection: A Multidisciplinary Approach to Surgical Management at a Community Hospital. Am Surg. 2020;86(9):1215-1217. doi:10.1177/0003134820933596\u003c/li\u003e\n\u003cli\u003eSardiwalla Y, Nachmani O, Price E, Huynh M, Coroneos C, McRae M. Upper Extremity Infection Related to Intravenous Drug Use: Considering the True Cost of the COVID-19 Pandemic and Lockdown. HAND. 2023;18(6):999-1004. doi:10.1177/15589447221077377\u003c/li\u003e\n\u003cli\u003eSimon R, Snow R, Wakeman S. Understanding why Patients with Substance use Disorders Leave the Hospital against Medical Advice: A Qualitative Study. Subst Abuse. 2020;41(4):519-525. doi:10.1080/08897077.2019.1671942\u003c/li\u003e\n\u003cli\u003eWeingart SN, Davis RB, Phillips RS. Patients discharged against medical advice from a general medicine service. J Gen Intern Med. 1998;13(8):568-571. doi:10.1046/j.1525-1497.1998.00169.x\u003c/li\u003e\n\u003cli\u003eHwang SW, Li J, Gupta R, Chien V, Martin RE. What happens to patients who leave hospital against medical advice? CMAJ Can Med Assoc J J Assoc Medicale Can. 2003;168(4):417-420.\u003c/li\u003e\n\u003cli\u003eGarland A, Ramsey CD, Fransoo R, et al. Rates of readmission and death associated with leaving hospital against medical advice: a population-based study. Can Med Assoc J. 2013;185(14):1207-1214. doi:10.1503/cmaj.130029\u003c/li\u003e\n\u003cli\u003eChan ACH, Palepu A, Guh DP, et al. HIV-Positive Injection Drug Users Who Leave the Hospital Against Medical Advice: The Mitigating Role of Methadone and Social Support.\u003c/li\u003e\n\u003cli\u003eJAIDS J Acquir Immune Defic Syndr. 2004;35(1):56-59. doi:10.1097/00126334-200401010-00008\u003c/li\u003e\n\u003cli\u003eDunleavy K, Munro A, Roy K, et al. Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. Drug Alcohol Depend. 2017;174:91-97. doi:10.1016/j.drugalcdep.2017.01.020\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1: Patient Characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCharacteristic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eData\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eNumber of patients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003ePatient age (years), median, [interquartile range]\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e34 [28 - 49]\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003ePatient sex, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e21 (55.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e17 (44.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eLocation of infection, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eUnilateral hand\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e22 (57.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eUnilateral upper arm\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e11 (28.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eBilateral hands\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e3 (7.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eUnilateral wrist\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e2 (5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eBilateral upper arm\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eBilateral wrists\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eComorbidities, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eCigarette smoking\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e31 (81.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eIntravenous drug use\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e19 (50)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eType 2 diabetes mellitus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e7 (18.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eEnd-stage renal disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e1 (2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003eTaking immunosuppressive medication\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e1 (2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003ePast medical history, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.62237762237763%\" valign=\"top\"\u003e\n \u003cp\u003ePrevious soft tissue infection requiring surgical management\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.377622377622377%\" valign=\"top\"\u003e\n \u003cp\u003e10 (26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2: Course in Hospital\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCharacteristic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eData\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eLength of stay, median [interquartile range], days\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e6 [4-14.5]\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eTime from presentation to operation, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eWithin 24 hours\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e22 (57.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003e24 \u0026ndash; 48 hours\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e11 (28.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eOver 48 hours\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e3 (7.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eType of procedure, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eIncision and drainage\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e26 (68.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eIrrigation and debridement\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e10 (26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eAmputation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e2 (5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eImaging investigations, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eUS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e6 (15.8)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e4 (10.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eMRI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e2 (5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eLaboratory investigations, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eWound culture\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e36 (94.7)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eCBC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e35 (94.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eMetabolic panel\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e34 (89.5)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eLactate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e23 (60.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eCRP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e21 (55.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eBlood culture\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e16 (42.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eLFT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e16 (42.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eCK\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e13 (34.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eDisposition, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eHome or community\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e18 (47.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"77.81512605042016%\" valign=\"top\"\u003e\n \u003cp\u003eLeft against medical advice\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.18487394957983%\" valign=\"top\"\u003e\n \u003cp\u003e10 (26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Harm Reduction, Necrotizing Fasciitis, Soft Tissue Infections, Substance Abuse Intravenous","lastPublishedDoi":"10.21203/rs.3.rs-4004749/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4004749/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Skin and soft tissue infections (SSTIs) are a leading cause of hospital admission and engagement with the health care system amongst people who inject drugs (PWID). The current study aims to describe the epidemiology of SSTIs requiring surgical intervention in Saskatoon, Canada.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: This retrospective chart review assessed patients with a primary diagnosis of upper limb SSTIs requiring surgical intervention at St. Paul’s Hospital and Royal University Hospital (Saskatoon, Canada) between January 1 and December 31, 2020.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: 38 eligible patients with a median age of 34 years and M:F of 21:17 were identified. 31 (81.6%) smoked cigarettes and 19 (50.0%) used intravenous drugs. A majority of SSTIs were unilateral infections involving the hand 22 (57.9%) or upper arm 11 (28.9%). Ten (26.3%) patients had a prior SSTI requiring surgical management. Necrotizing fasciitis was diagnosed in 7 (18.4%) patients, two of which, required amputation of the affected hand or arm. The median length of hospital stay was 6 days (IQR: 4 – 14.5). Ten patients left the hospital against medical advice, before completion of treatment; of these patients, 8 (80.0%) were PWID.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: Harm reduction strategies may help address the rising incidence and recurrence of SSTIs in the injection drug use population. Involvement of addiction services and social work during hospital admission may reduce the rate of patient-directed discharge, facilitating the completion of treatment. Furthermore, increased access to needle exchange programs in the community may reduce the number of SSTIs caused by contaminated injection equipment in the PWID population.\u003c/p\u003e","manuscriptTitle":"Epidemiology of upper limb skin and soft tissue infections requiring surgical intervention in Saskatoon, Canada: A retrospective chart review","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-03-06 19:28:24","doi":"10.21203/rs.3.rs-4004749/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1b3194a8-7e7b-4ef4-b421-5d07810496b1","owner":[],"postedDate":"March 6th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-03-12T16:27:14+00:00","versionOfRecord":[],"versionCreatedAt":"2024-03-06 19:28:24","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4004749","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4004749","identity":"rs-4004749","version":["v1"]},"buildId":"WrCJVZZCHTDjtuVLN7oU0","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}